Immuno-oncology is a promising new front on the fight against cancer. Exploiting the existence of tumor-specific antigens, immunotherapies aim to entrain the body’s immune system to specifically target and destroy cancer cells.

Systematic and reliable profiling of cytokine levels from minimally invasive biofluid samples affords valuable information about patient immune response, therapy progress, and key immune mechanisms that can be leveraged for novel or personalized treatments. LUNARIS™ Kits enable precise, multiplexed protein profiling that is being thoroughly tested in the context of immune-oncology applications, including risk assessment based on cytokine levels as prognostic markers in blood cancer treatment.